{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KqC3c4KDA","lastupdate":"2024-05-28T00:00:00.000Z","update_date":"2024-05-28T00:00:00.000Z","lastModified":"Mar 13, 2025","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"galimedix-therapeutics","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$6FiRU3LkqQZWrY2NGnaiNRVDpcNyLhpy1PTFKzFnthDAGkn5gKDlVG","name":"Galimedix Therapeutics","oneliner":"Novel Treatment for Neurodegenerative Diseases of the Eye and Brain","registrar":"515669174","website":"https://galimedix.com","careerspage":"","founded_month":6,"founded_year":2017,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/42904523","instagram":""},"social":["https://www.linkedin.com/company/42904523"],"flattenedsociallinks":"https://www.linkedin.com/company/42904523","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":10,"patent":1,"raised":2000000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases.\nGalimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta plays a role, such as in dry AMD, glaucoma and Alzheimer’s disease: Galimedix’s initial areas of focus.\n\nIts amyloid beta-targeting approach is strongly supported by our license deal with a major ophthalmology player, as well as recent successes in the field of Alzheimer’s disease. \n\nGalimedix’s approach blocks a key step in the neurodegenerative process with a highly specific, well tolerated small molecule without impacting normal neuronal function. This key step – the formation of toxic oligomers and protofibrils of amyloid beta (Aβ) – has emerged as a central cause of neurodegeneration. This understanding is supported by recent approvals and by positive late-stage clinical results with Aβ-targeting therapies for Alzheimer’s disease, as well as numerous publications about the role of Aβ in dry AMD and glaucoma.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97249905139","country":null,"address":{"israeli":[{"id":"14bd0a14-cf8d-4237-b25c-55afafe56fa5","city":"Shorashim","type":null,"address":"Shorashim, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"f53eaf23-9902-420a-90d2-575d4b3b9deb","city":"Kensington","address":"3704 Calvend Lane, Kensington, MD, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"North District","news":[{"id":"4rGKrKWxOIEUYTTHIHidIkdCpUtVrKlm0EBjy1PxyCUOuWYmCA6S0I","date":"Mar 8, 2024","link":"https://finance.yahoo.com/news/galimedix-therapeutics-presents-scientific-data-090000116.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Development, Alzheimers Treatment","company":"Galimedix Therapeutics, Inc.","layoffs":"N/A","summary":"Galimedix Therapeutics, Inc. has announced encouraging data for its orally available small molecule GAL-201, which has shown potential in models of Alzheimer’s disease (AD). The molecule belongs to a new pharmacological class of amyloid beta aggregation modulators that act upstream of other known Aβ-targeting agents. The data was presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2024: advances in science and therapy). The next step for Galimedix is to move GAL-201 towards IND submission and clinical development.","partners":"Théa Open Innovation (TOI)","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Alzheimers Treatment","Clinical Development","GAL-201","Neuroprotective Therapies","IND Submission"],"date_of_event":"March 08, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"t2VeeHyKOcp8vQx7NNK4PCdRLqe0JzKfyeTpKiKbfU7S2HbyOaty19","news_summary":"Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"SJBKCSmFpq3UomujljDdkTmnzD7h1rPynzhwGnMGGVTtGFa0RXFHWe","date":"Feb 28, 2024","link":"https://www.eqs-news.com/news/corporate/galimedix-therapeutics-announces-new-pre-clinical-data-with-gal-201-in-an-alzheimers-disease-transgenic-model-to-be-presented-at-ad-pd-2024-conference/2004947","source":"www.eqs-news.com","visible":1,"analysis":{"tags":"Research, Alzheimers Treatment","company":"Galimedix Therapeutics, Inc.","layoffs":"N/A","summary":"Galimedix Therapeutics, a Phase 2 clinical-stage biotechnology company, has announced the presentation of new pre-clinical data with GAL-201, a small molecule designed to target amyloid beta (Aβ) and suppress the formation of toxic Aβ aggregates in the brains of people with Alzheimer’s disease (AD). The data will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2024) in Lisbon, Portugal. The data shows the beneficial effects of GAL-201 in a transgenic mouse model of AD, indicating its potential as a treatment for AD.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Alzheimers Treatment","Pre-clinical Data","GAL-201","AD/PD™ 2024 Conference","Neurodegenerative Diseases"],"date_of_event":"28.02.2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment","acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8qkcvUuOE76SbAsualQwNUQPcCXOtLuU5xQTzEqpWntuWHkbnTMUOq","news_summary":"Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference | Corporate - EQS News","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"66a9ed96-d044-45d2-828f-e3dddc83a884","date":"Oct 29, 2019","link":"https://www.globenewswire.com/news-release/2019/10/29/1936978/0/en/Galimedix-Therapeutics-Inc-s-GAL-101-Gains-from-Target-Validation-by-Positive-Phase-3-Results-of-Biogen-s-Aducanumab.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"neurodegenerative diseases, Alzheimers disease, amyloid beta oligomers, breakthrough, validation","company":"Galimedix Therapeutics, Inc.","layoffs":null,"summary":"Galimedix Therapeutics, Inc. announced that the recent positive results of a Phase 3 study in Alzheimer’s disease with Biogen’s aducanumab also validate the target of the company’s lead molecule, GAL-101. GAL-101 has the advantage of being a small molecule and blocks the formation of all forms of toxic oligomers at source while the antibody eliminates them only after their formation. Galimedix considers the recently announced aducanumab results in Alzheimer’s disease to be validation for GAL-101 eyedrops, which target the same amyloid beta pathology in dry macular degeneration (AMD) and glaucoma. The company is developing a Phase 2 program in these two indications using GAL-101 eyedrops. An additional oral formulation of GAL-101 is also in development for Alzheimers disease.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Alzheimers disease","amyloid beta oligomers","GAL-101","eye drops","neuroprotection"],"date_of_event":"October 29, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B9JW4jXl7XC6GGVj0MLt5EyqSBPLH3AQPy1bVPtouHrgX0QiE1F4r2","news_summary":"Galimedix Therapeutics, Inc.'s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen's Aducanumab","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"572f5466-6883-4078-91ee-b1939251c822","date":"May 8, 2019","link":"https://www.globenewswire.com/news-release/2019/05/08/1819313/0/en/Preclinical-Studies-Demonstrate-Galimedix-Therapeutics-Investigational-Compound-GAL-101-Shows-Neuroprotective-Effect-from-Toxic-Amyloid-Beta-in-Dry-AMD-and-Glaucoma-Models.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Research, Ophthalmic Diseases","company":"Galimedix Therapeutics","layoffs":"Not mentioned","summary":"Galimedix Therapeutics, a company developing solutions for ophthalmic and neurodegenerative diseases, has presented data showing that its investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules. The compound may also provide sustained detoxification. The data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The companys Chief Scientific Officer, Dr. Hermann Russ, commented that the unique mechanism of GAL-101 has been shown to reduce the levels of amyloid beta present in the retina, thereby preventing neurodegeneration and increasing the chances of preventing vision loss.","partners":"Tel Aviv University","customers":"Not mentioned","investors":"Tel Aviv University","confidence":9,"key_topics":"GAL-101, Neuroprotection, Amyloid Beta, Ophthalmology, Research","date_of_event":"May 08, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Ml18cPDoOCqUXSupN8Frv40yEOl1EQYw1GVLgRG3BS5pvY00UXfvUD","news_summary":"Preclinical Studies Demonstrate Galimedix Therapeutics' Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"22cea739-f1ac-4223-91ea-c4d91145a588","date":"Feb 6, 2019","link":"https://www.globenewswire.com/news-release/2019/02/06/1711498/0/en/Galimedix-Therapeutics-Presents-Data-Showing-Safety-Tolerability-and-Potential-for-Efficacy-of-Its-Investigational-Eyedrops-Containing-GAL-101-at-Glaucoma-360-Conference.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"ophthalmic, neurodegenerative diseases","company":"Galimedix Therapeutics","layoffs":null,"summary":"Galimedix Therapeutics presented an overview of data on its compound GAL-101, which has shown potential in preventing the formation of toxic amyloid beta oligomers in ophthalmic diseases. The company also presented positive safety and tolerability data from its Phase 1 study. GAL-101 was shown to reach the retina quickly and have a sustained effect for weeks. Galimedix is currently planning and fundraising for a Phase 2 program. The company is a phase 2 ophthalmic pharmaceutical company with a novel drug addressing glaucoma and dry AMD using an eye drops delivery platform.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["GAL-101","amyloid beta","Phase 1 study","retinal ganglion cells","eye drops"],"date_of_event":"February 1, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cnF8qVwUuTIev96V6JSCMsEESdSTHN0xQocaDARsw4LNnmU4Jo8ATd","news_summary":"Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"441ece88-edd1-4ba6-a5bc-9b1b29f1b1c9","date":"Dec 11, 2018","link":"https://www.globenewswire.com/news-release/2018/12/11/1665167/0/en/Galimedix-Therapeutics-Appoints-Industry-Veteran-Hermann-Russ-M-D-Ph-D-Chief-Scientific-Officer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"appointment","company":"Galimedix","layoffs":null,"summary":"Galimedix Therapeutics has appointed Hermann Russ, M.D., Ph.D., as its chief scientific officer. Dr. Russ is an expert in the field of neurodegenerative diseases and has knowledge of the companys lead molecule for the treatment of degenerative diseases of the retina. His appointment is expected to contribute to the development of the company and bring a new treatment to patients suffering from degenerative diseases. Galimedix is a phase 2 ophthalmic pharmaceutical company that focuses on developing solutions for ophthalmic and neurodegenerative diseases. The companys novel drug, GAL-101, is delivered through eye drops and has shown promising results in animal models. Galimedix holds an exclusive worldwide license from Tel Aviv University for the drug.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["appointment","treatment","neurodegenerative diseases","eye drops","license"],"date_of_event":"December 1, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KsRluGDFZdTopzCUbaYawgJnunEOzp5kHORyLNDu2N3VFLwMJXuYtM","news_summary":"Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cae23117-1f8f-41f4-8651-0349c3f0ed2a","date":"Oct 21, 2018","link":"https://www.globenewswire.com/news-release/2019/10/21/1932657/0/en/Galimedix-Therapeutics-Inc-To-Present-at-the-BIO-Investor-Summit.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"pharmaceuticals, neurodegenerative diseases","company":"Galimedix Therapeutics, Inc.","layoffs":null,"summary":"Galimedix Therapeutics, Inc.s chief scientific officer will present and meet with investors at the BIO Investor Summit. The company is a Phase 2/3-ready ophthalmic pharmaceutical company developing a novel drug for glaucoma and dry AMD. Their most advanced compound, GAL-101, has shown promising results in animal models and has completed Phase 1 studies. The company is supported by leading experts in the field and is also exploring oral delivery of the drug. The announcement of the presentation at the BIO Investor Summit suggests positive growth opportunities for the company.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["BIO Investor Summit","Galimedixs drug development","GAL-101 eye drops","Phase 2/3-ready","Neurodegenerative diseases"],"date_of_event":"October 23, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B9vmr0PJA1GimrBpqGaqLFNlOfV4391oGiC3JonMqarbz6V0sxJEFF","news_summary":"Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":7,"techcommunityinvolvement":null,"mediagallery":[],"tags":["brain-disorder","drug-delivery","ophthalmology","visually-impaired","eye-diseases","glaucoma","drug-discovery","alzheimers-disease","degenerative-diseases"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2018-04-01","name":"EG30 for the treatment of Alzheimer disease","tags":["treatments","alzheimers-disease"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/ramot_tto_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda7","university_logo":"/image_cloud/ramot_institution_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["GAL-101","GAL-201"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$2M","totalrounds":1,"fundingstage":"Seed","totalfunding":"$2M","publicinvestors":2,"lastpublicfunding":2000000,"totalpublicrounds":1,"totalpublicfunding":2000000},"team":[{"name":" Alexander  Gebauer","email":"agebauer@galimedix.com","phone":"","gender":"Male","userid":"HYsyE53J69Fkd5VL0QVnak3MBtY25rycSgV5gV7S4PPHS0Cti3Bbtq","bounced":false,"claimed":null,"founder":0,"urlname":"alexander-gebauer","visible":1,"memberid":"KjUauuvrPVkyWzMZoPr2YMDYgN3GHJnUalHJLUhRJImAkCn2QYKE5x","position":"Co-founder & Executive Chairman","last_name":"Gebauer","claimtoken":"IsgUQLkvmFwyPB022ZMFHcZo5xwrd9XFjGWHnGjNJcXExddkIxYIct","first_name":" Alexander ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/alexander-gebauer-3928b05a/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-05-28 17:31:40.000000","initials":" G","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Phylis K. Bellin","email":"pbellin@galimedix.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Nr8opIJDA","bounced":false,"claimed":0,"founder":0,"urlname":"phylis-k-bellin","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgypq5lAoM","position":"CFO & Board Member","last_name":"K. Bellin","claimtoken":"rxNHaFzEszBiNoOnT1HCGEV5G5K10eT6oeyxIDj4asCMQqOjZf7gRx","first_name":"Phylis","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/phyllis-bellin-09036712/","unsubscribed":false,"is_activeuser":1,"additionalemail":"phylis@galimedix.com","claimedemaildate":"2024-05-28 17:24:12.000000","initials":"PK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Christopher Parsons","email":"chris@galimedix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Nr8uIMJDA","bounced":true,"claimed":0,"founder":1,"urlname":"christopher-parsons","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgmvHInAkM","position":"Co-Founder, Chief Pharmacologist & VP of Non-Clinical Development","last_name":"Parsons","claimtoken":"111099c5228c3dc9d7d278b2b751d0fa0cc3b2fe427747662e1669db3735f574","first_name":"Christopher","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/christophergparsons/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2019-11-10 06:49:02.000000","initials":"CP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Herman Russ","email":"hruss@galimedix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Nqc7P0JDA","bounced":false,"claimed":0,"founder":1,"urlname":"herman-russ","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg6qbZigkM","position":"Co-founder & CSO","last_name":"Russ","claimtoken":"4HoB0rEMaB7ijFxZfFfuKJQRI8wW8mOMgmAaklg3VGQXE9NyOhXfsn","first_name":"Herman","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/hermann-russ-m-d-ph-d-96a62979/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2025-03-13 15:08:12.000000","initials":"HR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Andrew  Pearlman","email":"apearlman@galimedix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OrMqewIDA","bounced":false,"claimed":0,"founder":1,"urlname":"andrew-pearlman","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg6rq-2AsM","position":"Co-founder & President","last_name":"Pearlman","claimtoken":"vq34QMIGsJtPVvBo1tohhkVBdquzGmLnasIWFTBAKHbCGOOiMtcmKy","first_name":"Andrew ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/andrew-pearlman-0783808/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-05-28 17:24:09.000000","initials":"AP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yaniv  Barkana","email":"ybarkana@galimedix.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Mqhx9MLDA","bounced":false,"claimed":0,"founder":0,"urlname":"yaniv-barkana","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgyqrjqwsM","position":"CMO","last_name":"Barkana","claimtoken":"p3vHWyuBXc70FS5yVkcrIxGDnLH0nWshAQ6ra6JtIgpiXTkQCFbyPi","first_name":"Yaniv ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yanivbarkana/","unsubscribed":false,"is_activeuser":1,"additionalemail":"yanivbarkana@gmail.com","claimedemaildate":"2025-03-13 15:08:16.000000","initials":"YB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2019-11-10T00:00:00.000Z","crunchbaseid":"galimedix-therapeutics","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yanina Wainscheinker","creator_email":"yanina.wain@gmail.com","createdate":"2019-11-07T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"hi7B5WgX08j41C851mMXZfxBCFwbJQozbTnCcWNq5VTJzbtlr9vW0p","date":"Jan 2019","amount":"$2M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"InFocus Capital Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/infocus-capital-partners","logokey":"$ugufMRMtHGaCb5hVoWorENdYrbDxVBED8Dz5j73JarYg5z9gHbLhR0.png","tagline":null,"urlname":"/investor_page/infocus-capital-partners","isisraeli":0,"investorid":"RVvhjqBuOJurt2mSrbSsb2qGMZ8iLq2B8mzPN8MgYeUaj7xOJH4Kiz","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bPKWsEZneG0rFRlZ9V3MlkBXYrPrh1130bBrYD5lOfJ5z0gMrJ4Ons","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ugufMRMtHGaCb5hVoWorENdYrbDxVBED8Dz5j73JarYg5z9gHbLhR0.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Rimonci Capital","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cq1J9i4m61O2WfSa4xewaPDmk44gfqXA7Z2Q4CCIyKoQgKEy6OLNem","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/2017","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Galimedix Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$6FiRU3LkqQZWrY2NGnaiNRVDpcNyLhpy1PTFKzFnthDAGkn5gKDlVG","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$6FiRU3LkqQZWrY2NGnaiNRVDpcNyLhpy1PTFKzFnthDAGkn5gKDlVG","seoabout":"Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":6,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"hi7B5WgX08j41C851mMXZfxBCFwbJQozbTnCcWNq5VTJzbtlr9vW0p","date":"Jan 2019","amount":"$2M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"InFocus Capital Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/infocus-capital-partners","logokey":"$ugufMRMtHGaCb5hVoWorENdYrbDxVBED8Dz5j73JarYg5z9gHbLhR0.png","tagline":null,"urlname":"/investor_page/infocus-capital-partners","isisraeli":0,"investorid":"RVvhjqBuOJurt2mSrbSsb2qGMZ8iLq2B8mzPN8MgYeUaj7xOJH4Kiz","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bPKWsEZneG0rFRlZ9V3MlkBXYrPrh1130bBrYD5lOfJ5z0gMrJ4Ons","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ugufMRMtHGaCb5hVoWorENdYrbDxVBED8Dz5j73JarYg5z9gHbLhR0.png","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Rimonci Capital","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cq1J9i4m61O2WfSa4xewaPDmk44gfqXA7Z2Q4CCIyKoQgKEy6OLNem","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}